Chronic Kidney Disease Clinical Trial
Official title:
Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability
Verified date | October 2017 |
Source | CHU de Reims |
Contact | Fatouma TOURE |
Phone | 0326787638 |
ftoure[@]chu-reims.fr | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Bioimpedance is recently known to be a reliable, reproducible and validated technic allowing
determination of hydratation status in patients with chronic kidney disease treated with
peritoneal dialysis (PD). Overhydratation attested by bioimpedance is strongly associated
with cardio-vascular morbidity and mortality in patients with PD. Overhydratation might
concern more than half of patients at PD initiation, though the underlying mechanism remains
unknown.
High peritoneal permeability (HPP) might concern about a third of patients starting a PD,
although only a few datas are published on this condition. HPP at initiation of PD is
associated with a decrease in both technical and patient survival and might be responsible of
ultrafiltration failure. The underlying mechanisms of HPP at initiation of PD also remains
unknown.
To our knowledge, the correlation between hydratation status and peritoneal permeability at
initiation of peritoneal dialysis remains unknown. Moreover, there is no datas concerning the
cinetic evolution of peritoneal permeability; demographic or biologic factors associated with
HPP in days and months following PD start.
The aim of the present study is to correlate hydratation status (attested by bioimpedance)
and peritoneal permeability at early start of peritoneal dialysis. Thus, we investigated
early cinetic of peritoneal permeability at different time point during the first year of
peritoneal dialysis and we analyzed the demographical and biological factors associated with
HPP and overhydratation during this period.
This study is a prospective, multicentric cohort study. Fourty patients recruited in a two
years' period in five centers of nephrology will be included. Hydratation status will be
determined with Fluid Overload measurement by bioimpedance technic thanks to BCM system
(Fresenius Medical Care®). Peritoneal permeability will be determined by modified Peritoneal
Equilibration Test with complete drainage at sixty minutes. Datas will prospectively be
collected, including: weight, blood pressure, diuretic posology, diuresis, PD modality,
dialysate prescribed.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | November 1, 2020 |
Est. primary completion date | November 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - End stage chronic kidney disease - Ambulatory - Starting a peritoneal dialysis in one of the participant centers - Accepting the study protocol - Age > 18yo Exclusion criteria: - Age <18yo - Protected by the law |
Country | Name | City | State |
---|---|---|---|
France | Damien JOLLY | Reims |
Lead Sponsor | Collaborator |
---|---|
CHU de Reims |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hydratation status | Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®) FO < 10th percentile = extracellular dehydration 10th percentile < FO < 90th percentile = extracellular normohydration FO > 90th percentile = extracellular hyperhydration |
Day 7 | |
Secondary | Peritoneal permeability | Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky " High ": D/P creatinine>0,8; D/D0 glucose<0,25 " High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38 " Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48 " Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49. |
Day 7 | |
Secondary | Hydratation status | Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®) FO < 10th percentile = extracellular dehydration 10th percentile < FO < 90th percentile = extracellular normohydration FO > 90th percentile = extracellular hyperhydration |
Day 45 | |
Secondary | Peritoneal permeability | Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky " High ": D/P creatinine>0,8; D/D0 glucose<0,25 " High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38 " Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48 " Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49. |
Day 45 | |
Secondary | Hydratation status | Fluid overload (FO) measured with BMC bioimpedance system (Fresenius medical care®) FO < 10th percentile = extracellular dehydration 10th percentile < FO < 90th percentile = extracellular normohydration FO > 90th percentile = extracellular hyperhydration |
Day 365 | |
Secondary | Peritoneal permeability | Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky " High ": D/P creatinine>0,8; D/D0 glucose<0,25 " High average ": 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38 " Low average ": 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48 " Low " : D/P creatinine<0,5 ; D/D0 glucose>0,49. |
Day 365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |